Bora Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Bora Pharmaceuticals has been growing earnings at an average annual rate of 39.9%, while the Pharmaceuticals industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 34.9% per year. Bora Pharmaceuticals's return on equity is 25.5%, and it has net margins of 23.1%.

Key information

39.89%

Earnings growth rate

38.66%

EPS growth rate

Pharmaceuticals Industry Growth	5.95%
Revenue growth rate	34.89%
Return on equity	25.46%
Net Margin	23.05%
Last Earnings Update	31 Dec 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bora Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:BORA.Y Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 25	19,014	4,383	3,886	672
30 Sep 25	21,097	4,242	4,100	770
30 Jun 25	21,319	5,126	4,107	781
31 Mar 25	20,868	5,964	4,133	789
31 Dec 24	17,427	4,116	3,444	639
30 Sep 24	15,508	4,252	2,837	525
30 Jun 24	13,556	3,282	2,231	430
31 Mar 24	12,277	2,707	1,641	336
31 Dec 23	14,200	3,030	1,444	298
30 Sep 23	16,293	2,868	1,344	272
30 Jun 23	15,942	2,704	1,212	238
31 Mar 23	14,158	2,252	1,056	176
31 Dec 22	10,494	1,392	862	129
30 Sep 22	6,346	1,128	687	57
30 Jun 22	4,811	697	586	38
31 Mar 22	4,650	594	571	41
31 Dec 21	4,900	750	585	41
30 Sep 21	4,418	1,045	637	40
30 Jun 21	3,626	963	578	39
31 Mar 21	2,794	868	507	37
31 Dec 20	1,800	578	441	37
30 Sep 20	1,523	191	300	37
30 Jun 20	1,513	232	293	38
31 Mar 20	1,521	262	280	39
31 Dec 19	1,529	305	259	40
30 Sep 19	1,517	355	217	38
30 Jun 19	1,492	283	236	41
31 Mar 19	1,515	267	227	41
31 Dec 18	1,372	443	220	38
30 Sep 18	1,107	351	200	36
30 Jun 18	846	330	141	28
31 Mar 18	525	274	116	23
31 Dec 17	358	14	87	20
30 Sep 17	323	17	81	19
30 Jun 17	297	22	74	18
31 Mar 17	291	24	73	18
31 Dec 16	283	25	71	18
30 Sep 16	273	23	68	18
30 Jun 16	260	18	69	18
31 Mar 16	247	26	67	17
31 Dec 15	238	34	65	17
30 Sep 15	236	30	65	13
30 Jun 15	234	28	68	12

Quality Earnings: BORA.Y has a large one-off gain of NT$3.0B impacting its last 12 months of financial results to 31st December, 2025.

Growing Profit Margin: BORA.Y's current net profit margins (23.1%) are lower than last year (23.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BORA.Y's earnings have grown significantly by 39.9% per year over the past 5 years.

Accelerating Growth: BORA.Y's earnings growth over the past year (6.5%) is below its 5-year average (39.9% per year).

Earnings vs Industry: BORA.Y earnings growth over the past year (6.5%) did not outperform the Pharmaceuticals industry 6.6%.

Return on Equity

High ROE: BORA.Y's Return on Equity (25.5%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/10 21:22
End of Day Share Price	2026/04/08 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bora Pharmaceuticals Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jianzheng Wu	Capital Securities Corporation
Chenghsin Lin	J.P. Morgan
null null	KGI Securities Co. Ltd.